ONCY Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 14:48):

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer...

Stats
Today's Volume	80 918.00
Average Volume	383 691
Market Cap	77.70M
EPS	$0 ( 2024-03-07 )
Next earnings date	( $-0.0900 ) 2024-05-03
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.43
ATR14	$0.00500 (0.49%)

Volume Correlation

Long: 0.04 (neutral)

Short: -0.79 (moderate negative)

Signal:(43.053) Neutral

Oncolytics Biotech Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Oncolytics Biotech Inc Correlation - Currency/Commodity

0.21
( neutral )

0.08
( neutral )

0.00
( neutral )

0.24
( neutral )

Oncolytics Biotech Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-403 000 (0.00 %)
EPS:	$-0.410

Q4	2023
Revenue:	$0
Gross Profit:	$-107 000 (0.00 %)
EPS:	$-0.0536

Q3	2023
Revenue:	$0
Gross Profit:	$-103 000 (0.00 %)
EPS:	$-0.140

Q2	2023
Revenue:	$0
Gross Profit:	$-96 000.00 (0.00 %)
EPS:	$-0.120

Financial Reports:

No articles found.

Oncolytics Biotech Inc

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.